H.B. Fuller (NYSE:FUL) Bolsa

H.B. Fuller

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

H.B. Fuller Co

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

FULHAM SHORE PLC by FULHAM SHORE PLC

FULLNET COMMUNS INC by FullNet Communications, Inc.

Fullnet Communications Inc

Fulton Financial Corporation - Common Stock

Fulton Financial Corp

Fulton Financial Corporation - Depositary Shares Each Representing a 1/40th Interest in a Share of Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A

J.P. Morgan analyst Jeffrey J. Zekauskas maintained an Underweight rating on H. B. Fuller Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) on Thursday, <a target="_blank" href="https://www.benzinga.com/quote/FUL/analyst-ratings" rel="noreferrer noopener">lowering the price forecast from $60 to $50.</a>
The company reported first-quarter results, where net revenue<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44502655/h-b-fuller-reports-first-quarter-2025-results" rel="noreferrer noopener"> was $789 million,&nbsp;down 2.7% year over year.</a>
Organic revenue was up 1.9% year-on-year, driven by improved volume.
The analyst notes that H.B. Fuller&#8217;s performance showed negative year-over-year comparisons, primarily due to the underperformance of its Health, Hygiene, and Consumable segment.
Despite flat sales in the segment at $368 million, its EBITDA dropped by 25%, from $62.9 million to $46.9 million, continuing a trend of weakness that began in the previous quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44537936/consumer-inflation-expectations-skyrocket-in-march-hit-highest-levels-in-32-years" rel="noreferrer noopener">Consumer Inflation Expectations Skyrocket In March, Hit Highest Levels In 32 Years</a>
Per Zekauskas, this drop was partly due to the company previously benefiting from declining raw material costs, which have now leveled off, leading to reduced price adjustments.
While raw material costs for waxes and tackifying resins increased year-over-year, no sequential inflation was noted.
On the other hand, H.B. Fuller&#8217;s Engineering and Building Adhesive Solutions segments showed more positive results, the analyst writes.
Zekauskas expects H.B. Fuller&#8217;s adjusted EBITDA to grow by about 1% in FY2025, from $594 million to $597 million.
The company is expected to face a negative EBITDA comparison in the first quarter of FY25, with the second quarter EBITDA likely staying flat year-over-year.
The analyst suggests the firm may lower its earnings guidance after 2Q of FY25, especially considering a softer U.S. macro environment. Additionally, Fuller&#8217;s $100 million solar panel business in the Engineering Adhesives segment could see a 20% sales contraction, causing a $5 million year-over-year EBITDA decline due to oversupply in the Chinese solar market.
The key focus for Fuller will be improving price realizations in the HHC segment to restore profitability and margins, the analyst writes.
Price Action: FUL stock is down 5.6% at $54.38 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44541993/kinder-morgan-set-for-q1-growth-amid-rising-lng-demand-says-analyst" target="_blank" rel="noreferrer noopener">Goldman Sachs Forecasts High Gas Prices And LNG Demand Drive Kinder Morgan&#8217;s Revenue</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

News

Price Target

Reiteration

Markets

Analyst Ratings

Trading Ideas

General

JP Morgan Slashes H.B. Fuller Price Forecast For Softening Growth

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $62.5, with a high estimate of $72.00 and a low estimate of $50.00. Observing a downward trend, the current average is 11.66% lower than the prior average price target of $70.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1743166860_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of H.B. Fuller by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to H.B. Fuller. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of H.B. Fuller compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of H.B. Fuller's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of H.B. Fuller's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on H.B. Fuller analyst ratings.</a>
<h2>About H.B. Fuller</h2>
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
<h3>Key Indicators: H.B. Fuller's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, H.B. Fuller showcased positive performance, achieving a revenue growth rate of 2.26% as of 30 November, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: H.B. Fuller's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.8%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.4%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): H.B. Fuller's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.15%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: H.B. Fuller's debt-to-equity ratio is below the industry average at 1.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: H.B. Fuller In The Eyes Of 4 Experts

JP Morgan analyst Jeffrey Zekauskas maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Underweight and lowers the price target from $60 to $50.

JP Morgan Maintains Underweight on H.B. Fuller, Lowers Price Target to $50

WIIM

H.B. Fuller shares are trading higher after the company reported better-than-expected Q1 financial results.

Operating cash flow in fiscal year 2025 is expected to be between $300 million and $325 million. Adjusted EBITDA for the second quarter of 2025 is expected to be in the range of $150 million to $160 million.

Guidance

H.B. Fuller Says FY25 Outlook Remains Unchanged; Net Revenue Growth Expected To Be Down 2% - 4%, Adjusted EPS To Be $3.90 - $4.20 (Est $3.97)

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.50 by 8 percent. This is a 19.4 percent decrease over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $788.66 million which beat the analyst consensus estimate of $769.19 million by 2.53 percent. This is a 2.68 percent decrease over sales of $810.42 million the same period last year.

Earnings

Earnings Beats

H.B. Fuller Q1 2025 Adj EPS $0.54 Beats $0.50 Estimate, Sales $788.66M Beat $769.19M Estimate

H.B. Fuller Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) will release its first-quarter financial results, after the <a href="https://www.benzinga.com/quote/ful/earnings">closing bell, on Wednesday, March 26.</a>
Analysts expect the Saint Paul, Minnesota-based company to report quarterly earnings at 50 cents per share, down from 67 cents per share in the year-ago period. H.B. Fuller projects quarterly revenue of $769.11 million, compared to $810.42 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 15, H.B. Fuller posted weaker-than-expected fourth-quarter earnings.
H.B. Fuller shares fell 1.1% to close at $53.83 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/FUL/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Seaport Global analyst Michael Harrison downgraded the stock from Buy to Neutral on March 5, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Deutsche Bank analyst David Begleiter maintained a Buy rating and cut the price target from $75 to $72 on Jan. 22, 2025. This analyst has an accuracy rate of 73%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Underweight rating and slashed the price target from $70 to $60 on Jan. 17, 2025. This analyst has an accuracy rate of 67%.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44471817/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

H.B. Fuller Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

<h3>Companies Reporting Before The Bell</h3>
• Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is estimated to report quarterly loss at $5.00 per share on revenue of $5.60 million. 
• Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is projected to report quarterly earnings at $2.18 per share on revenue of $8.23 billion. 
• Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $3.20 billion. 
• Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $384.72 million. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.60 billion. 
• SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) is expected to report quarterly loss at $0.03 per share on revenue of $202.71 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $152.00 million. 
• CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $358 thousand. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $80.10 million. 
• JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly loss at $0.46 per share on revenue of $3.59 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $1.35 billion. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $88.50 million. 
• Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is expected to report quarterly loss at $2.94 per share on revenue of $4.28 million. 
• Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) is expected to report earnings for its fourth quarter. 
• Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is projected to report quarterly earnings at $1.48 per share on revenue of $1.51 billion. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) is estimated to report earnings for its fourth quarter. 
• Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) is likely to report earnings for its fourth quarter. 
• TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) is likely to report earnings for its fourth quarter. 
• Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $40.63 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is projected to report quarterly loss at $0.11 per share on revenue of $114.96 million. 
• BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is projected to report quarterly loss at $0.87 per share on revenue of $20 thousand. 
• Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is projected to report earnings for its fourth quarter. 
• Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $6.91 million. 
• Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $14.21 million. 
• Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is expected to report earnings for its fourth quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $33.09 million. 
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $1.97 billion. 
• Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $2.10 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $797.68 million. 
• Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is expected to report quarterly loss at $0.06 per share on revenue of $1.35 million. 
• Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $21.40 million. 
• Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $276.82 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $3.01 per share on revenue of $2.47 billion. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is projected to report earnings for its fourth quarter. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $790.90 million. 
• Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $320.52 million. 
• Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) is expected to report quarterly loss at $0.26 per share on revenue of $232 thousand. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $918.88 million. 
• Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $87.50 million. 
• Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $1.56 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

ALVO

BCDA

CATX

CHWY

CLGN

CMCM

CNXC

CTAS

DERM

DLTR

DOOO

DRRX

DTIL

DYAI

GRDN

ITRG

MLKN

MVIS

OXBR

PAYX

SAIL

SNAL

Spruce Power Holding Corporation Class A Common Stock

SPRU

TATT

TTAM

USIO

VRNT

WOOF

ZEPP

Earnings Scheduled For March 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Bernie McTernan downgraded Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) from Buy to Hold and maintained the price target of $9. Beyond shares closed at $5.90 on Tuesday. <a href="https://www.benzinga.com/quote/BYON/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Patrick Wood downgraded Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) from Overweight to Equal-Weight and lowered the price target from $45 to $22. Tandem Diabetes Care shares closed at $19.49 on Tuesday. <a href="https://www.benzinga.com/quote/TNDM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Michael Harrison downgraded H.B. Fuller Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) from Buy to Neutral. H.B. Fuller shares closed at $54.94 on Tuesday. <a href="https://www.benzinga.com/quote/FUL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Maheep Mandloi downgraded Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Outperform to Neutral and lowered the price target from $11 to $1. Sunnova Energy Intl shares closed at $0.6748 on Tuesday. <a href="https://www.benzinga.com/quote/NOVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Daniel Tricarico downgraded the rating for CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) from Sector Outperform to Sector Perform and lowered the price target from $52 to $46. CubeSmart shares closed at $41.80 on Tuesday. <a href="https://www.benzinga.com/quote/CUBE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

BYON

CUBE

NOVA

TNDM

This H.B. Fuller Company Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.5, a high estimate of $78.00, and a low estimate of $60.00. A 9.74% drop is evident in the current average compared to the previous average price target of $77.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741183255_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive H.B. Fuller is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to H.B. Fuller. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of H.B. Fuller compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of H.B. Fuller's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into H.B. Fuller's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on H.B. Fuller analyst ratings.</a>
<h2>Get to Know H.B. Fuller Better</h2>
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
<h3>Unraveling the Financial Story of H.B. Fuller</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: H.B. Fuller displayed positive results in 3 months. As of 30 November, 2024, the company achieved a solid revenue growth rate of approximately 2.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: H.B. Fuller's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.8%, the company may face hurdles in effective cost management.
Return on Equity (ROE): H.B. Fuller's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.4%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): H.B. Fuller's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.15%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: H.B. Fuller's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.13, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into H.B. Fuller Stock: Analyst Perspectives (4 Ratings)

Seaport Global analyst Michael Harrison downgrades H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) from Buy to Neutral.

Downgrades

Seaport Global Downgrades H.B. Fuller to Neutral

Ratings for H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.5, with a high estimate of $78.00 and a low estimate of $60.00. Experiencing a 9.74% decline, the current average is now lower than the previous average price target of $77.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737554468_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of H.B. Fuller by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to H.B. Fuller. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of H.B. Fuller compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of H.B. Fuller's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into H.B. Fuller's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FUL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on H.B. Fuller analyst ratings.</a>
<h2>Delving into H.B. Fuller's Background</h2>
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
<h3>Key Indicators: H.B. Fuller's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, H.B. Fuller showcased positive performance, achieving a revenue growth rate of 1.92% as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: H.B. Fuller's net margin is impressive, surpassing industry averages. With a net margin of 6.03%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): H.B. Fuller's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): H.B. Fuller's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.12%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.1, H.B. Fuller faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Buy and lowers the price target from $75 to $72.

Deutsche Bank Maintains Buy on H.B. Fuller, Lowers Price Target to $72

JP Morgan analyst Jeffrey Zekauskas maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Underweight and lowers the price target from $70 to $60.

JP Morgan Maintains Underweight on H.B. Fuller, Lowers Price Target to $60

Fiscal 2025 Outlook:
<ul>
<li>Net revenue growth for fiscal 2025 is expected to be down 2% to 4%, adjusting for the divestiture of the Flooring business, net revenue is expected to be up 1% to 2%;</li>
<li>Organic revenue growth is expected to be flat to up 2% versus fiscal 2024;</li>
<li>Adjusted EBITDA for fiscal 2025 is expected to be in the range of $600 million to $625 million, equating to growth of approximately 1% to 5% year-on-year;</li>
<li>Adjusted EBITDA for the first quarter of 2025 is expected to be in the range of $105 million to $115 million;</li>
<li>The core tax rate, excluding the impact of discrete items, is anticipated to be between 26% and 27% in fiscal year 2025;</li>
<li>Net interest expense for fiscal 2025 is expected to be between $120 million and $125 million;</li>
<li>Adjusted EPS (diluted) is expected to be in the range of $3.90 to $4.20, equating to a range of up 2% to 9% year-on-year;</li>
<li>Operating cash flow in fiscal year 2025 is expected to be between $300 million and $325 million;</li>
<li>Capital expenditures of approximately $160 million are expected in fiscal 2025, which includes approximately $40 million related to the Company's manufacturing footprint consolidation initiative.</li>
</ul>

H.B. Fuller Fiscal 2025 Outlook, Sees Net Revenue Down 2%-4%; Organic Growth Flat To Up 2%; Adjusted EBITDA $600M-$625M, Q1 $105M-$115M; Adj. EPS $3.90-$4.20 Vs $4.22 Est.; Cash Flow $300M-$325M

The Q4 earnings report for H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) was released on Wednesday, January 15, 2025 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
H.B. Fuller missed estimated earnings by -8.0%, reporting an EPS of $0.92 versus an estimate of $1.0.
Revenue was up $20.41 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company missed on EPS by $0.1 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at H.B. Fuller's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.23</td>
<td>1.03</td>
<td>0.64</td>
<td>1.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.13</td>
<td>1.12</td>
<td>0.67</td>
<td>1.32</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>944.25M</td>
<td>913.23M</td>
<td>825.03M</td>
<td>932.16M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>917.93M</td>
<td>917.11M</td>
<td>810.42M</td>
<td>902.88M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
H.B. Fuller management provided guidance for FY 2024, expecting earnings between $3.84 and $3.84 per share.
To track all earnings releases for H.B. Fuller <a href="https://www.benzinga.com/quote/FUL/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

H.B. Fuller Earnings Report: Q4 Overview

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) reported quarterly earnings of $0.92 per share which missed the analyst consensus estimate of $1.00 by 8 percent. This is a 30.3 percent decrease over earnings of $1.32 per share from the same period last year. The company reported quarterly sales of $923.28 million which beat the analyst consensus estimate of $916.77 million by 0.71 percent. This is a 2.26 percent increase over sales of $902.88 million the same period last year.

Earnings Misses

H.B. Fuller Q4 Adj EPS $0.92 Misses $1.00 Estimate, Sales $923.28M Beat $916.77M Estimate

<h3>Companies Reporting Before The Bell</h3>
• BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) is likely to report quarterly earnings at $11.21 per share on revenue of $5.53 billion. 
• Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) is likely to report earnings for its third quarter. 
• JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) is likely to report quarterly earnings at $4.04 per share on revenue of $41.56 billion. 
• Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) is estimated to report quarterly earnings at $8.27 per share on revenue of $12.33 billion. 
• Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) is expected to report quarterly earnings at $1.24 per share on revenue of $19.41 billion. 
• Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) is projected to report quarterly earnings at $1.54 per share on revenue of $4.63 billion. 
• Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is projected to report quarterly earnings at $1.26 per share on revenue of $20.28 billion. 
<h3>Companies Reporting After The Bell</h3>
• Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $256.67 million. 
• Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) is likely to report quarterly earnings at $1.15 per share on revenue of $566.76 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.92 per share on revenue of $904.32 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is likely to report quarterly earnings at $3.07 per share on revenue of $2.44 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HOMB

Earnings Scheduled For January 15, 2025

Citigroup analyst Patrick Cunningham maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Neutral and lowers the price target from $78 to $68.

Comments

H.B. Fuller

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL